First-in-class treatment delivers major advance for incurable kidney disease

The latest findings from the PROTECT phase III trial show sparsentan—a novel treatment for IgA nephropathy—significantly reduces proteinuria, or abnormal protein levels in the urine, compared to standard treatment irbesartan.

source https://medicalxpress.com/news/2023-04-first-in-class-treatment-major-advance-incurable.html